Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing innovative immunology therapies, announced it has entered into a securities purchase agreement with institutional and accredited investors for the sale of 5,208,333 American Depositary Shares (ADSs) at $0.48 per ADS, along with accompanying Series A and Series B warrants. Additionally, the company separately executed a warrant inducement agreement with an existing investor. The combined transactions are expected to generate approximately $2.61 million in gross proceeds, with closing anticipated on or about April 27, 2026, subject to customary conditions.
The company stated that the proceeds from these transactions will be used to support the expansion of its contract development and manufacturing organization (CDMO) platform, advance customer programs, and continue investment in its immunotherapy pipeline. This capital infusion comes at a critical time as Scinai seeks to bolster its operational capabilities and bring its therapeutic candidates closer to market.
Scinai Immunotherapeutics is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., a CDMO that provides development and manufacturing services to biotechnology and pharmaceutical companies. The expansion of the CDMO platform is expected to enhance the company’s ability to serve its clients and generate additional revenue streams.
The announcement underscores the company’s commitment to strengthening its financial position while pursuing its strategic objectives. The private placement and warrant inducement provide Scinai with the necessary capital to invest in its core business areas without diluting existing shareholders excessively.
For more information about the company and its latest developments, visit its newsroom at https://ibn.fm/SCNI. The full press release can be accessed at https://ibn.fm/6Vw4O.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Scinai Immunotherapeutics Secures $2.61M in Private Placement and Warrant Inducement to Fund CDMO Expansion.